Please read and agree to the
terms and conditions
of this site.
I agree
Medical Technology
/tech
Clear filters and search
Format
photo
Tags
clinical trials
4
×
life sciences
national blog main
boston blog main
boston top stories
drugs
boston
san francisco blog main
san francisco top stories
accelerated approval
acute hepatic porphyria
aldehyde
aldeyra therapeutics
allergan
allergic conjunctivitis
alnylam pharmaceuticals
aminolevulinic acid
bristol-myers squibb
cannabidiol
clinical data
dravet syndrome
dry eye disease
epidiolex
fda
fen-phen
fenfluramine
genfit
gilead sciences
givosiran
gw pharmaceuticals
intercept pharmaceuticals
ldl-c
lennox-gastaut syndrome
liver
liver disease
madrigal pharmaceuticals
mark pruzanski
nash
national top stories
new york
What
data
4
×
drug
medicine
4
×
new
approved
fda
market
pharmaceuticals
ago
aldeyra
alnylam
battle
cannabis
cleared
closer
derivative
disclosed
disease
epilepsy
eye
far
fatty
fighting
filing
form
gw
gw’s
horizon
inflammation
intercept
interference
known
liver
marijuana
marketed
multiple
nasdaq
nash
nonalcoholic
ok
Language
Current search:
data
×
medicine
×
" clinical trials "
×
@xconomy.com
5 years ago
New Data Puts Aldeyra One Step Closer to FDA Filing for Eye Drug
@xconomy.com
5 years ago
With New Data, Intercept On Track for First-Ever Approved NASH Drug
@xconomy.com
5 years ago
With New Data, Alnylam Could Seek Speedy OK For Second RNAi Drug
@xconomy.com
5 years ago
Zogenix Epilepsy Data Sets Up Market Battle With GW’s Cannabis Drug